HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

[1]  A. Mocroft,et al.  High rate of hepatitis C virus (HCV) recurrence in HIV‐infected individuals with spontaneous HCV RNA clearance , 2014, HIV medicine.

[2]  A. Muir.  The Rapid Evolution of Treatment Strategies for Hepatitis C , 2014, The American Journal of Gastroenterology.

[3]  A. Mocroft,et al.  Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis , 2014, AIDS.

[4]  P. Vanhems,et al.  Liver-related death among HIV/HCV coinfected indivi duals, implications for the era of directly acting ant ivirals , 2014 .

[5]  A. Mocroft,et al.  Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? , 2013, Journal of hepatology.

[6]  A. Mocroft,et al.  Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA* , 2013, HIV medicine.

[7]  A. Mocroft,et al.  Stability of hepatitis C virus (HCV) RNA levels among interferon‐naïve HIV/HCV‐coinfected individuals treated with combination antiretroviral therapy , 2013, HIV medicine.

[8]  Anders Karlsson,et al.  Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients , 2013, PloS one.

[9]  A. Mocroft,et al.  Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? , 2012 .

[10]  A. Mocroft,et al.  Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients , 2012, AIDS.

[11]  K. Schønning,et al.  Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals , 2012, AIDS.

[12]  A. Mocroft,et al.  A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study , 2011, HIV clinical trials.

[13]  M. Manns,et al.  Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Mocroft,et al.  Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression , 2009, Journal of acquired immune deficiency syndromes.

[15]  J. Kaldor,et al.  Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Mocroft,et al.  Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. , 2008, The Journal of infectious diseases.

[17]  V. Soriano,et al.  Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. , 2007, AIDS research and human retroviruses.

[18]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[19]  A. Mocroft,et al.  Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C , 2006, Scandinavian journal of infectious diseases.

[20]  C. Andrzejewski,et al.  BMC Infectious Diseases , 2006 .

[21]  A. Mocroft,et al.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.

[22]  A. Mocroft,et al.  Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection? , 2005, Antiviral therapy.

[23]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[24]  A. Mocroft,et al.  Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. , 2005, AIDS research and human retroviruses.

[25]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[26]  J. Goedert,et al.  Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. , 2001, The Journal of infectious diseases.

[27]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.